Mayo Foundation for Medical Education and Research

Anand G Patel

Scott H Kaufmann

This document provides methods and materials involved in assessing responsiveness to PARP inhibitors and platinating agents. For example, methods and materials for using levels of non-homologous end-joining pathway members (e.g., artemis mRNA or polypeptide levels, Ku80 mRNA or polypeptide levels, or DNA-PKcs mRNA or polypeptide levels) to determine if cancer cells that are homologous recombination-deficient are likely to be susceptible or resistant to PARP inhibitors and platinating agents are provided.

Methods and materials for assessing responsiveness to PARP inhibitors and platinating agents

This document relates to methods and materials involved in assessing samples for enzyme-nucleic acid complexes. For example, methods and materials for using antibodies to determine the presence, absence, or amount of enzyme-nucleic acid complexes (e.g., human topoisomerase I-DNA complexes) in a sample (e.g., a biological sample such as a tissue biopsy) are provided.

Growing community of inventors

Rochester, MN, United States of America

Anand G Patel